Enliven Therapeutics, Inc. 4

CFO Benjamin Hohl exercised 6,018 Enliven Therapeutics (ELVN) options at $2.48 and sold 6,018 common shares around $43–45, leaving direct holdings of 51,000 shares.

On June 17, 2026, Enliven Therapeutics CFO Benjamin Hohl exercised 6,018 stock options at $2.48 per share and acquired an equivalent number of common shares, then sold a total of 6,018 common shares in three open-market transactions at weighted average prices of $42.785, $43.8634, and $44.7475 under a pre-arranged Rule 10b5-1 trading plan, resulting in a net effect of monetizing options while keeping his overall direct ownership at 51,000 shares, which are valued at roughly the mid‑$40s per share based on the reported sale prices. The option was fully vested and exercisable, and certain of his holdings include RSUs, each representing the right to receive one share of common stock subject to vesting; after these transactions, his direct equity stake remains significant in dollar terms even though the day’s activity reflects a non-incremental, option-exercise-and-sell sequence rather than a net open-market purchase.

Filing Facts

CIK

1672619

Ticker

ELVN

Form

4

Source Type

sec

Accession

0001882764-26-000005

Alert Tier

6